#USA #New York #Faruqi & Faruqi #James Wilson #Baxter International

Investigation Overview

Faruqi & Faruqi, LLP, a prominent law firm specializing in securities litigation, has launched an investigation into Baxter International Inc. (NYSE: BAX) concerning potential claims on behalf of investors who suffered losses. This investigation arises from significant concerns regarding the company's Novum LVP (Large Volume Pump) medical devices, which are alleged to have systemic defects leading to severe malfunctions.

Background of Baxter International

Baxter International, a leading global healthcare company, has been a trusted name for decades, known for its innovative products and commitment to patient safety. However, recent developments have raised eyebrows among investors and consumers alike. Allegations suggest that various flaws in the Novum LVP may expose patients to life-threatening risks, including incidents of underinfusion, overinfusion, and even complete failures in delivering fluids.

Legal Landscape

As part of the probe, Faruqi & Faruqi is examining whether Baxter’s executives violated federal securities laws by providing false or misleading information about the safety and efficacy of its products. Reports indicate that Baxter was aware of multiple malfunctions and incidents of harm resulting from these defects but failed to take adequate remedial measures.

The investigation also coincides with a federal securities class action lawsuit against Baxter, in which investors have until December 15, 2025, to apply for the role of lead plaintiff. The lead plaintiff typically acts on behalf of others in the class, guiding the litigation process and ensuring the interests of all affected parties are represented.

Impact on Investors

The alleged failure of Baxter to maintain transparency about the Novum LVP devices culminated in a significant drop in the company’s stock price. Following an announcement on July 31, 2025, that the company would temporarily halt shipments and installations of the Novum LVP, shares plummeted by 22.4% to a closing price of $21.76. This dramatic turn of events underscores the importance of investor vigilance and highlights the potential risks associated with healthcare investments.

Call to Action

James (Josh) Wilson, a senior partner at Faruqi & Faruqi, encourages all investors who suffered losses due to their investment in Baxter within the specified period (from February 23, 2022, to July 30, 2025) to reach out for a discussion about their legal rights. Whether or not investors wish to lead class action efforts or simply want more information about their options, the firm is ready to assist.

Faruqi & Faruqi is committed to advocating for investors’ rights, having successfully recovered hundreds of millions since its inception in 1995. They actively seek information from whistleblowers, former employees, or other parties with insights into Baxter's practices. This case serves as a reminder of the balance between innovation in healthcare and the duty to ensure patient safety and transparency.

Future Updates

Investors and interested parties can follow updates regarding this ongoing investigation and news surrounding Baxter International on the firm's official website or through their contact channels. With a pressing deadline approaching, those impacted are urged to act swiftly to protect their rights and pursue any potential recovery.

For further information, interested individuals can visit Faruqi & Faruqi's website or contact Josh Wilson at 877-247-4292 or 212-983-9330 ext. 1310. Legal advice is provided with strict confidentiality, emphasizing the firm’s dedication to client privacy and successful outcomes in all cases.